BioSpace News Archive

It is a condition of urologic malignancy happening in the human body at the site of tissue of the urinary bladder.

OraSure Technologies, Inc. has scheduled its regular earnings conference call covering 2021 second quarter financial results and certain business developments for 5:00 pm ET on Tuesday, August 3, 2021.

Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its 2021 second quarter operating results on Thursday, August 5, 2021, after market close.

Sientra, Inc., a medical aesthetics company uniquely focused on plastic surgeons, announced that it will release financial results for the second quarter of 2021 after the close of trading on Tuesday, August 10, 2021.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2021 on Monday, August 9 at 4:30 p.m. ET / 1:30 p.m. PT.

Masimo announced its financial results for the second quarter of 2021, ended July 3, 2021.

Avinger, Inc., commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease, announced that it will release its financial results for the second quarter 2021 after the close of trading on Tuesday, August 10, 2021.

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, and Zai Lab Limited (NASDAQ:ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, announced today that patient enrollment in the ATTACK Phase 3 registrational clinical trial of sulbactam-durlobactam (SUL-DUR) is now complete, with top-line data readout anticipated early in the fourth quarter of 2021.

Talis Biomedical Corporation (“TLIS”), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that it will release financial results for the second quarter after market close on Tuesday, August 10, 2021.

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that its Chief Executive Officer Nima Farzan will participate in the 2021 Wedbush PacGrow Healthcare Conference, being held virtually from August 10-11, 2021.